Formulation and characterisation of solid lipid nanoparticle hydrogels of naproxen
DOI:
https://doi.org/10.33974/8r7rqm47
Keywords:
Naproxen, Solid lipid nanoparticles, Bioavailability, Span 80, Tween 80Abstract
Naproxen is Non-steroidal anti-inflammatory drug (NSAID) and is considered to be first line drug in treatment of rheumatoid arthritis, osteo arthritis and ankylosing spondylitis. Naproxen undergoes first pass metabolism when taken orally and it also produces some GI problems. The aim of the study is to improve the efficacy, drug loading capacity and biocompatibility of drug by formulating in solid lipid nanoparticles. To minimize the toxicity and increase the stability of drug by encapsulating in nanoparticulate system. To optimize the developed solid lipid nanoparticle formulations. Drug Naproxen has been loaded with lipid carriers and then formulated in to Hydrogels with the objective of prolonging its action and avoiding its most side effects by incorporation of solid lipid carriers which is achieved by Nanostructured lipid carrier (NLC). Nanostructured lipid carrier was prepared by Ultra sonication or High-Speed Homogenization method. Characterization of nanostructured lipid carrier was performed by measuring particle size, drug entrapment efficiency and in-vitro drug release. Spherical uniform particles (size below 500 nm), Drug entrapment efficiency was found to be in the range of about 69-86%. The drug release profile of all the formulations after 24 h study was found to be in the range of 43%- 94%. Formulation showing sustained release profile at the end of the study was found to be the best formulation. Optimized formulation was converted in to hydrogel with Carbopol as gelling agent was formulated and characterized for its physical appearance, pH, viscosity, spreadability, homogeneity studies. The result concludes that Naproxen loaded nanostructured lipid carrier could be a potential drug delivery system.
Downloads
References
Shekelle, P. G., Newberry, S. J., FitzGerald, J. D., Motala, A., O'Hanlon, C. E., Tariq, A., Okunogbe, A., Han, D., & Shanman, R. (2017). Management of gout: A systematic review in support of an American College of Physicians clinical practice guideline. *Annals of Internal Medicine, 166*(1), 37-51. https://doi.org/10.7326/M16-1386
Phillips, W. J., & Currier, B. L. (2004). Analgesic pharmacology: II. Specific analgesics. *Journal of the American Academy of Orthopaedic Surgeons, 12*(4), 221-233. https://doi.org/10.5435/00124635-200407000-00003
Dawood, M. Y. (2006). Primary dysmenorrhea: Advances in pathogenesis and management. *Obstetrics & Gynecology, 108*(2), 428-441. https://doi.org/10.1097/01.AOG.0000222316.51795.78
Oyler, D. R., Parli, S. E., Bernard, A. C., Chang, P. K., Procter, L. D., & Harned, M. E. (2015). Nonopioid management of acute pain associated with trauma: Focus on pharmacologic options. *Journal of Trauma and Acute Care Surgery, 79*(3), 475-483. https://doi.org/10.1097/TA.0000000000000784
Zacher, J., Altman, R., Bellamy, N., Brühlmann, P., Da Silva, J., Huskisson, E., & Taylor, R. S. (2008). Topical diclofenac and its role in pain and inflammation: An evidence-based review. *Current Medical Research and Opinion, 24*(4), 925-950. https://doi.org/10.1185/030573508X296606
van den Bekerom, M. P. J., Sjer, A., Somford, M. P., Bulstra, G. H., Struijs, P. A. A., & Kerkhoffs, G. M. M. J. (2015). Non-steroidal anti-inflammatory drugs (NSAIDs) for treating acute ankle sprains in adults: Benefits outweigh adverse events. *Knee Surgery, Sports Traumatology, Arthroscopy, 23*(8), 2390-2399. https://doi.org/10.1007/s00167-014-3130-5
May, J. J., Lovell, G., & Hopkins, W. G. (2007). Effectiveness of 1% diclofenac gel in the treatment of wrist extensor tenosynovitis in long distance kayakers. *Journal of Science and Medicine in Sport, 10*(1), 59-65. https://doi.org/10.1016/j.jsams.2006.02.001
Barkin, R. L. (2015). Topical nonsteroidal anti-inflammatory drugs: The importance of drug, delivery, and therapeutic outcome. *American Journal of Therapeutics, 22*(5), 388-407. https://doi.org/10.1097/MJT.0000000000000226
Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature New Biology, 231*(25), 232-235. https://doi.org/10.1038/newbio231232a0
Chaiamnuay, S., Allison, J. J., & Curtis, J. R. (2006). Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. *American Journal of Health-System Pharmacy, 63*(19), 1837-1851. https://doi.org/10.2146/ajhp060178
Scott, L. J. (2012). Intravenous ibuprofen: In adults for pain and fever. *Drugs, 72*(8), 1099-109. https://doi.org/10.2165/11210190-000000000-00000
Sostres, C., Gargallo, C. J., Arroyo, M. T., & Lanas, A. (2010). Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin, and coxibs) on upper gastrointestinal tract. *Best Practice & Research Clinical Gastroenterology, 24*(2), 121-132. https://doi.org/10.1016/j.bpg.2010.01.003
Whelton, A. (1999). Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. *American Journal of Medicine, 106*(5B), 13S-24S. https://doi.org/10.1016/S0002-9343(99)00456-4
Harirforoosh, S., Asghar, W., & Jamali, F. (2013). Adverse effects of nonsteroidal anti-inflammatory drugs: An update of gastrointestinal, cardiovascular, and renal complications. *Journal of Pharmacy and Pharmaceutical Sciences, 16*(5), 821-847. https://doi.org/10.18433/J3JG6G
Sriuttha, P., Sirichanchuen, B., & Permsuwan, U. (2018). Hepatotoxicity of nonsteroidal anti-inflammatory drugs: A systematic review of randomized controlled trials. *International Journal of Hepatology, 2018*, 5253623. https://doi.org/10.1155/2018/5253623
Schafer, A. I. (1999). Effects of nonsteroidal anti-inflammatory therapy on platelets. *American Journal of Medicine, 106*(5B), 25S-36S. https://doi.org/10.1016/S0002-9343(99)00457-6
Berkes, E. A. (2003). Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. *Clinical Reviews in Allergy & Immunology, 24*(2), 137-148. https://doi.org/10.1385/CRIAI:24:2:137
Szczeklik, A. (1987). Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. *Annals of Allergy, 59*(5 Pt 2), 113-118. https://doi.org/10.1016/S1081-1206(10)62398-6
Rothenberg, R. J., & Holcomb, J. P. (2000). Guidelines for monitoring of NSAIDs: Who listened? *Journal of Clinical Rheumatology, 6*(5), 258-265. https://doi.org/10.1097/00124743-200010000-00002
Hunter, L. J., Wood, D. M., & Dargan, P. I. (2011). The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. *Open Access Emergency Medicine, 3*, 39-48. https://doi.org/10.2147/OAEM.S19902
Lima, T. A. M. d., Furini, A. A. d. C., Atique, T. S. C., Di Done, P., Machado, R. L. D., & Godoy, M. F. d. (2016). Analysis of potential drug interactions and adverse reactions to nonsteroidal anti-inflammatory drugs among the elderly. *Revista Brasileira de Geriatria e Gerontologia, 19*, 533-544. https://doi.org/10.1590/1981-22562016019.160011
Abdulla, A., Adams, N., Bone, M., Elliott, A. M., Gaffin, J., Jones, D., et al. (2013). Guidance on the management of pain in older people. *Age and Ageing, 42*(Suppl 1), i1–i57. https://doi.org/10.1093/ageing/aft063
Published
License
Copyright (c) 2024 Narasimha Rao, Rini Joy, Nelson Kumar, Gowtham Kumar Reddy, Hari Babu (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
